Uncategorized
EYEGUARD-B study reaches target exacerbation event
The phase 3 EYEGUARD-B study of gevokizumab reached its target exacerbation event, according to a Xoma press release.The EYEGUARD-B study is a randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s disease uveitis. The study is sponsored by Servier, the release said.